Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 47 patents granted in the last 365 days
The Florida International University Board of Trustees has 6 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners, meaning each examiner is responsible for 1 pending matter. This 1 to 1 ratio between actions and examiners shows a lack of examiner-specific concentration in the current workload. Consequently, the university must manage 6 separate prosecution tracks without the benefit of examiner-level familiarity across cases.
The portfolio's activity spans 5 distinct art units, showing a technical footprint across multiple areas. COLEMAN, BRENDA LIBBY is the busiest examiner with 1 pending office action, matching the count of every other examiner involved. For the legal team, this distribution across 5 distinct art units requires managing multiple simultaneous examiner relationships rather than focusing on 1 point of contact. This variety in art units indicates that the biotechnology and pharmaceutical innovations cover 5 different sub-specialties.
With 6 pending office actions and 6 distinct examiners, the prosecution environment is decentralized. The presence of 5 distinct art units involves multiple supervisory chains within the patent office. Because COLEMAN, BRENDA LIBBY only handles 1 pending office action, there is no examiner whose decisions disproportionately affect the overall portfolio of 6 actions. This structure necessitates a case-by-case approach to prosecution rather than a unified examiner-specific strategy.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| ALAWADI, SARAH | 1 | 37.5% | +38.4% |
| KOVACH, KARA NICOLE | 1 | 85.7% | +100.0% |
| KOLKIN, ADAM D. | 1 | 46.9% | +5.1% |
| GERIDO, DWAN A | 1 | 58.0% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18340240 | MULTI-SPECIES REFERENCE LADDER AND MULTI-PLEX PCR KIT AND USES THEREOF | KOVACH, KARA NICOLE | 26d |
| 18945850 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | COLEMAN, BRENDA LIBBY | — |
| 18292258 | NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | ALAWADI, SARAH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17468966 | SYSTEM AND METHOD FOR LABEL-FREE SINGLE MOLECULE DETECTION | GERIDO, DWAN A | 14d |
| 18340240 | MULTI-SPECIES REFERENCE LADDER AND MULTI-PLEX PCR KIT AND USES THEREOF | KOVACH, KARA NICOLE | 26d |
| 18945850 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | COLEMAN, BRENDA LIBBY | — |
| 18292258 | NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | ALAWADI, SARAH | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1681 | 1 |
| 3798 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18945850 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | COLEMAN, BRENDA LIBBY | — | §101DP | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18292258 | NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | ALAWADI, SARAH | 1619 | §103§112 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18340240 | MULTI-SPECIES REFERENCE LADDER AND MULTI-PLEX PCR KIT AND USES THEREOF | KOVACH, KARA NICOLE | 1681 | §103§112 | Non-Final OA | 26d | Pending | Jun 23, 2023 |
| 18306012 | SYSTEMS AND METHODS FOR PERFORMING PERIPHERAL VASCULAR IMAGING | KOLKIN, ADAM D. | 3798 | §103 | Non-Final OA | 41d | Pending | Apr 24, 2023 |
| 17468966 | SYSTEM AND METHOD FOR LABEL-FREE SINGLE MOLECULE DETECTION | GERIDO, DWAN A | 1797 | §103 | Final Rejection | 14d | Pending | Sep 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial